UCDCCC NCTN U10 Program

UCDCCC NCTN U10 项目

• 批准号: 8838065
• 负责人: DAVID R GANDARA
• 金额: $ 63.02万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-14 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8838065
• 关键词: Address; American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Area; Awareness; Basic Science; Biometry; California; Cancer Center; Cancer Control; Cancer Patient; Catchment Area; Center for Translational Science Activities; Clinical; Clinical Investigator; Clinical Nursing Research; Clinical Research; Clinical Trials; Coal; Collaborations; Communities; Comprehensive Cancer Center; Ensure; Faculty; Funding; Genomics; Goals; Gynecologic Oncology Group; Health; Human; Image; Intervention; Laboratories; Lead; Leadership; Link; Malignant Neoplasms; Medical Oncology; Minority; Mission; Molecular Biology; National Cancer Institute; National Clinical Trials Network; Pathology; Patients; Performance; Play; Population; Principal Investigator; Radiation Oncology; Radiation Therapy Oncology Group; Radiology Specialty; Research Activity; Research Infrastructure; Research Personnel; Research Support; Resources; Role; Rural; Schools; Site; Southwest Oncology Group; Structure; Surgical Specialties; The Jackson Laboratory; Translational Research; Translations; United States National Institutes of Health; Universities; Veterinary Medicine; Xenograft procedure; acronyms; base; cancer care; cancer prevention; career development; comparative; design; experience; improved; innovation; laboratory facility; medical specialties; multidisciplinary; oncology program; outreach; patient population; programs; research study; tertiary care; tumor

DESCRIPTION (provided by applicant): As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer cares to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this applicatin to become a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, research nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the cooperative group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to national cooperative group activities, including SWOG, RTOG, GOG, ACRIN, and ACOSOG, as well as to other NCI-related committees and initiatives. Expanding this effort to the NCTN concept will increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. Continuing a strong track record in cooperative group translational and clinical research leadership, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for cooperative group trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials "hub" for accrual to NCI-sponsored studies throughout North-Central California, expansion to the NCTN creates a number of additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will achieve the coals of the NCTN and ensure robust accrual.

描述(申请人提供)：加州大学戴维斯分校综合癌症中心(UCDCCC)是加州北部内陆地区约600万人口的唯一一家由NCI指定的癌症中心，为数量庞大且不断增长的人口提供一级癌症护理，同时也是该地区专科癌症护理的第三转诊中心。为了使这一申请成为NCTN网络领先的学术参与网站，由医学博士David R Gandara和Richard K Valicenti领导，MD UCDCCC将利用已经建立的多学科癌症研究团队，这些研究人员来自内科肿瘤学、放射肿瘤学、外科专科、分子生物学/基因组学、病理学、放射学、生物统计学、研究护理和临床研究支持，在广泛的肿瘤类型和整个合作小组网络中提供临床试验、科学和行政领导以及NCTN研究的收益。UCDCCC及其教职员工对国家合作团体活动，包括SWOG、RTOG、GOG、ACRIN和ACOSOG，以及其他与NCI相关的委员会和倡议做出了长期和可靠的贡献。将这一努力扩展到NCTN概念将增加参与的范围和范围，包括整合更多的研究人员，并为新教师和初级调查人员提供职业发展机会。UCDCCC继续在合作组翻译和临床研究领导方面保持着强劲的记录，准备利用独特的机构优势作为合作组试验和临床研究的实验室资源 为假说驱动的临床研究做出贡献。20多年来，UCDCCC一直是NCI赞助研究的临床试验“枢纽”，扩展到NCTN为UCDCCC创造了许多额外的机会，既增加了主站点的收益，又通过UCDCCC癌症护理网络和附属站点将NCTN试验的访问扩展到社区，其中包括大量未得到充分服务的农村和少数族裔患者群体。总之，UCDCCC代表了一个与临床试验计划相联系的跨学科组织和领导结构，该计划将实现NCTN的优势并确保稳健的收益。